Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders

Creative Commons License

Kocaman G., Kahraman N., Gurkan Koseoglu B., Bilgic B., Matur Z., Ertas M., ...More

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.55, no.4, pp.330-336, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 55 Issue: 4
  • Publication Date: 2018
  • Doi Number: 10.5152/npa.2017.19257
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.330-336
  • Keywords: Temporomandibular disorders, headache, onabotulinumtoxinA, chronic migraine, TOXIN TYPE-A, PLACEBO-CONTROLLED PHASE, BOTULINUM-TOXIN, DOUBLE-BLIND, HEADACHE, PAIN, SYMPTOMS, RELIABILITY, POPULATION, PREVALENCE
  • Bezmialem Vakıf University Affiliated: Yes


Introduction: Migraine and temporomandibular disorders (TMD) are both common diseases and TMD are reported as a risk factor in migraine progression. OnabotulinumtoxinA is used in the treatment of chronic migraine (CM), and also has a potential role in TMD treatment. In this study, it is aimed to compare the efficacy of onabotulinumtoxinA treatment in CM patients with and without TMD.